carboprost
Generic: CARBOPROST TROMETHAMINE·Brand: CARBOPROST TROMETHAMINE, HEMABATE, Hemabate
carboprost: developed by 2 companies · 2 FDA decisions.
carboprost evidence translation
What we can confirm
2 FDA records
What it means
More than one developer is source-backed. Until you choose one, AI stays drug-only and does not guess ownership.
What to watch
Watch for new trials or company disclosures after the FDA record.
BioSniper AIPage evidence connected
Prepared research question
What is verified about carboprost, and what remains unknown?
Run cited research
Traceable citations · Unknowns marked
Development Pipeline (3)
| Company | Phase |
|---|---|
| ANI PHARMACEUTICALS INC (ANIP) | Approved |
| DR REDDYS LABORATORIES LTD (RDY) | Approved |
| DR REDDYS LABORATORIES LTD (RDY) | Approved |
FDA Decisions2 records
ApprovalINDICATIONS AND USAGE Carboprost tromethamine injection, USP is indicated for aborting pregnancy between the 13th and 20th weeks of gestation as calculated from the first day of the last normal menstrual period and in the following conditions related to second trimester abortion: 1. Failure of expulsion of the fetus during the course of treatment by another method; 2. Premature rupture of membranes in intrauterine methods with loss of drug and insufficient or absent uterine activity; 3. Requirem(RDY)FDA ↗
ANDA211941UNKNOWNStandardOtherInjectable
Frequently asked questions
Who is developing carboprost?
carboprost is being developed by ANI PHARMACEUTICALS INC, DR REDDYS LABORATORIES LTD.
What is carboprost's latest FDA decision?
The most recent tracked FDA decision for carboprost is Approval, dated January 25, 2024.